Study Details

Testing a Study Drug CMTX-101 Combined with Inhaled Tobramycin in People with Cystic Fibrosis Who Also Have Pseudomonas Aeruginosa

(IRB#: IRB_00171828)

This is a study to evaluate the new medication CMTX-101 in combination with inhaled Tobramycin in people with Cystic Fibrosis who also have Pseudomonas Aeruginosa. Cystic Fibrosis is a rare disease that mainly affects the lungs causing lung infections. Pseudomonas Aeruginosa is a type of bacteria (germ) that can cause infections in the body such as the lungs. Infections with Pseudomonas Aeruginosa are a leading cause of respiratory (breathing) failure and death in adults. The study will see if the drug will help people with the disease and is safe. People in the study will be treated with CMTX-101 in combination with inhaled Tobramycin. Being in the study requires about 35 days of participation. Including, 7 in-person visits at a study clinic and completing surveys. There are 2 parts of the study. People of part 1 will receive CMTX-101. People in part 2 will be randomly chosen to receive CMTX-101 or a placebo. The placebo looks like the drug but does not have the medication. People cannot be in both parts 1 and 2 of the study. Medical tests will be done during the study to track the health of participants.

I AM INTERESTED